Antibiotics for secondary prevention of coronary heart disease

Monk-Hansen, Tea; Prescott, Eva; Als‐Nielsen, Bodil; Hróbjartsson, Asbjørn; Wetterslev, Jørn; Gluud, Christian

doi:10.1002/14651858.cd003610

Cited by 3 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We updated our previous meta-analyses [2] with data from the extended follow-up of CLARICOR patients as well as data from new trials identified in January 2007 through searches in The Cochrane Library, PubMed, and EMBASE according to our protocol [7] . Meta-analyses followed the Cochrane Collaboration methodology [7] , including Review Manager [8] for calculation of relative risks with 95% CI with random-effect models and inconsistency ( I 2 ) as a measure of heterogeneity [9] .…”

Section: Statistical Analyses and Meta-analysesmentioning

confidence: 99%

See 1 more Smart Citation

Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease

et al. 2008

Self Cite

View full text Add to dashboard Cite

tients and updated meta-analyses. Methods: Centrally randomized, placebo controlled multicenter trial. All parties were blinded. Analyses were by intention to treat. Metaanalyses followed the Cochrane Collaboration methodology. Results: We randomized 4,372 patients with stable coronary heart disease to clarithromycin 500 mg (n = 2,172) or placebo (n = 2,200) once daily for 2 weeks. Mortality was followed through public register. Nine hundred and twentythree patients (21.1%) died. Six-year mortality was significantly higher in the clarithromycin group (hazard ratio 1.21, 95% confidence interval 1.06-1.38). Adjustment for entry characteristics (sex, age, prior myocardial infarction, center, and smoking) did not change the results (1.18, 1.04-1.35). Ad- Key WordsCoronary heart disease ؒ Clarithromycin ؒ Macrolides ؒ Antibiotics ؒ Cardiovascular mortality ؒ Chlamydia pneumoniae Abstract Objectives: We have reported increased 2.6-year mortality in clarithromycin-versus placebo-exposed stable coronary heart disease patients, but meta-analysis of randomized trials in coronary heart disease patients showed no significant effect of antibiotics on mortality. Here we report the 6-year mortality of clarithromycin-versus placebo-exposed pa-

show abstract

Section: Statistical Analyses and Meta-analysesmentioning

confidence: 99%

“…Meta-analyses followed the Cochrane Collaboration methodology [7] , including Review Manager [8] for calculation of relative risks with 95% CI with random-effect models and inconsistency ( I 2 ) as a measure of heterogeneity [9] .…”

Section: Statistical Analyses and Meta-analysesmentioning

confidence: 99%